I would argue that potential investors already know that our drug is a strong candidate for a number of additional indications.
In my opinion there is little benefit in choosing a second indication now and announcing it to the market, without the funding to properly follow it up. We're just committing ourself to a future path for no reason.
I would argue that potential investors already know that our...
-
- There are more pages in this discussion • 226 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.260M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 68013 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 8695 | 1 |
View Market Depth
| Last trade - 10.04am 16/08/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable